A Clinical Study of Pyrotinib in Patients of Advanced Colorectal Cancer With Her2 Variation
-
- STATUS
- Recruiting
-
- participants needed
- 40
-
- sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With Advanced HER2 Variation Colorectal Cancer
Description
Investigators identified HER2 amplification as a potential onco-driver and marker of de novo resistance to anti-EGFR therapy in mCRC patients for which other known genetic alterations conferring resistance to anti EGFR antibodies were excluded.
This study is an open-label Phase II, 2-sequential cohorts trial, assessing the response rate (ORR) of Pyrotinib (Cohort 1) or Trastuzumab combined Pyrotinib (Cohort 2), in metastatic colorectal patients harboring an amplified HER2 tumors .
HER2 positivity is centrally established by immunohistochemistry (IHC) and Silver In Situ Hybridization (SISH). To be HER2 eligible the original tumor, or the biopsied metastasis (whichever is last available), must be IHC 3+ or 2+ in more than 50% of cells, confirmed by SISH or FISH with a HER2:CEP17 ratio 2.0. For IHC a positive staining (3+) is defined as an intense membrane staining which can be circumferential, basolateral, or lateral of the tumor cells.
The study was a investigator-initiated multicenter clinical study to enroll 40 colorectal cancer patients with Her-2 Variation who were treated with either Pyrotinib alone or with Trastuzumab, 20 Patients in each group.The inclusion time was 1 year, and the follow-up time was 1 year. The Efficacy and Safety of Pyrotinib in Combination With or Without Trastuzumab in the treatment of Advanced Colorectal Cancer were evaluated with objective efficacy and safety as the main indicators.
Details
| Condition | Colorectal Cancer, Colorectal Cancer, Rectal disorder |
|---|---|
| Age | 18-75 years |
| Treatment | Pyrotinib, Pyrotinib in combination with trastuzumab |
| Clinical Study Identifier | NCT04380012 |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Last Modified on | 19 February 2024 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Add a private note
- Select a piece of text from the left.
- Add notes visible only to you.
- Send it to people through a passcode protected link.
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.